Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3193-3204

  Hunter, Terri B ^a   Manimala, Neil J ^a   Luddy, Kimberly A ^a   Catlin, Tracy ^a   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Paclitaxel; Small cell lung cancer; TRAIL

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PACLITAXEL; PROTEIN BCL XL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL KILLING; ENZYME ACTIVATION; FLOW CYTOMETRY; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LUNG SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; RECEPTORS, DEATH DOMAIN; SMALL CELL LUNG CARCINOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 80054758751     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Schiller JH, Adak S, Cella D, DeVore RF, 3rd and Johnson DH: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19(8): 2114-2122, 2001. (Pubitemid 32366966)
2. Masters GA, Declerck L, Blanke C et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21(8): 1550-1555, 2003. (Pubitemid 46594109)
3. Pujol JL, Daures JP, Riviere A et al.: Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93(4): 300-308, 2001. (Pubitemid 32219817)
4. Urban T, Chastang C, Lebas FX et al.: The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 86(11): 2238-2245, 1999. (Pubitemid 30010363)
5. Eckardt JR: Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 9(Suppl 6): 25-32, 2004.
6. Sandler AB: Irinotecan in small-cell lung cancer: the US experience. Oncology (Williston Park) 15(1 Suppl 1): 11-12, 2001.
7. Ardizzoni A, Manegold C, Debruyne C et al.: European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9(1): 143-150, 2003. (Pubitemid 36109726)
8. Eckardt JR: Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy. Oncology (Williston Park) 17(2): 181-188, 91; discussion 91-2, passim, 2003.
9. Amos LA and Lowe J: How Taxol stabilises microtubule structure. Chem Biol 6(3): R65-69, 1999. (Pubitemid 29363146)
10. Crown J and O'Leary M: The taxanes: an update. Lancet 355(9210): 1176-1178, 2000. (Pubitemid 30172946)
11. Vikhanskaya F, Vignati S, Beccaglia P et al.: Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 241(1): 96-101, 1998. (Pubitemid 28366583)
12. Yoo YD, Park JK, Choi JY et al.: CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clin Cancer Res 4(12): 3063-3068, 1998. (Pubitemid 29001482)
13. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90(20): 9552-9556, 1993. (Pubitemid 23315823)
14. Foss M, Wilcox BWL, Alsop GB and Zhang D: Taxol Crystals Can Masquerade as Stabilized Microtubules. PLoS ONE 3(1): e1476, 2008.
15. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA and Makowski L: Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 285(1): 197-203, 1999. (Pubitemid 29034037)
16. Rodi DJ and Makowski L: Similarity between the sequences of taxol-selected peptides and the disordered loop of the anti-apoptotic protein, Bcl-2. Pac Symp Biocomput, pp. 532-541, 1999.
17. Cao L, Sun D, Cruz T, Moscarello MA, Ludwin SK and Whitaker JN: Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J Neuroimmunol 108(1-2): 103-111, 2000. (Pubitemid 30438757)
18. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1): 21-27, 2002.
19. Javeed A, Ashraf M, Ghafoor A and Mukhtar MM: Paclitaxel and immune system. Eur J Pharm Sci 2009.
20. Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383-424, 1999. (Pubitemid 29449198)
21. Lamarca V and Scorrano L: When separation means death: killing through the mitochondria, but starting from the endoplasmic reticulum. EMBO J 28(12): 1681-1683, 2009.
22. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281(5381): 1322-1326, 1998. (Pubitemid 28406819)
23. Antignani A and Youle RJ: How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr Opin Cell Biol 18(6): 685-689, 2006. (Pubitemid 44692478)
24. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K and Yagita H: Type I Interferons (IFNs) Regulate Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Expression on Human T-cells: A Novel Mechanism for the Antitumor Effects of Type I IFNs. J Exp Med 189(9): 1451-1460, 1999. (Pubitemid 29227531)
25. Carrington PE, Sandu C, Wei Y et al.: The structure of FADD and its mode of interaction with procaspase-8. Mol Cell 22(5): 599-610, 2006. (Pubitemid 43817600)
26. Kaufmann M, Bozic D, Briand C et al.: Identification of a basic surface area of the FADD death effector domain critical for apoptotic signaling. FEBS Lett 527(1-3): 250-254, 2002. (Pubitemid 35253874)
27. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH and Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270(14): 7795-7798, 1995.
28. Peter ME: The TRAIL DISCussion: It is FADD and caspase-8! Cell Death Differ 7(9): 759-760, 2000.
29. Huang Y, Sheikh MS, Fornace AJ Jr. and Holbrook NJ: Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18(23): 3431-3439, 1999. (Pubitemid 29317338)
30. Huisman C, Ferreira CG, Broker LE et al.: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 8(2): 596-606, 2002. (Pubitemid 34193982)
31. Ofir R, Seidman R, Rabinski T et al.: Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 9(6): 636-642, 2002. (Pubitemid 34618869)
32. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A and Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279(49): 51057-51067, 2004. (Pubitemid 40017847)
33. Wieder T, Essmann F, Prokop A et al.: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97(5): 1378-1387, 2001. (Pubitemid 32183762)
34. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56(8): 1851-1854, 1996.
35. Berndtsson M, Konishi Y, Bonni A et al.: Phosphorylation of BAD at Ser-128 during mitosis and paclitaxel-induced apoptosis. FEBS Letters 579(14): 3090, 2005.
36. Li R, Moudgil T, Ross HJ and Hu HM: Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 12(3): 292-303, 2005. (Pubitemid 40360952)
37. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D and Bhalla KN: Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels. Cancer Res 61(2): 759-763, 2001. (Pubitemid 32128643)
38. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83(2): 151-156, 1999. (Pubitemid 29449089)
39. Bepler G, Jaques G, Koehler A, Gropp C and Havemann K: Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol 113(3): 253-259, 1987. (Pubitemid 17120600)
40. Bepler G, Jaques G, Neumann K, Aumuller G, Gropp C and Havemann K: Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol 113(1): 31-40, 1987. (Pubitemid 17017565)
41. Ribble D, Goldstein N, Norris D and Shellman Y: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnology 5(1): 12, 2005.
42. Casares N, Pequignot MO, Tesniere A et al.: Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202(12): 1691-701, 2005. (Pubitemid 41815875)
43. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411(6835): 380-384, 2001.
44. Park S-M, Schickel R and Peter ME: Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Current Opinion in Cell Biology 17(6): 610, 2005.
45. Huisman C, Ferreira CG, Broker LE et al.: Paclitaxel Triggers Cell Death Primarily via Caspase-independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460. Clin Cancer Res 8(2): 596-606, 2002. (Pubitemid 34193982)
46. Zhou H, Li X-M, Meinkoth J and Pittman RN: Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial Level. J Cell Biol 151(3): 483-494, 2000.
47. Zha J, Harada H, Yang E, Jockei J and Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87(4): 619-628, 1996. (Pubitemid 26386936)
48. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94(4): 481-490, 1998. (Pubitemid 28391864)
49. Antonia SJ, Mirza N, Fricke I et al.: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12(3 Pt 1): 878-887, 2006. (Pubitemid 43259871)
50. Wheeler CJ, Das A, Liu G, Yu JS and Black KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10(16): 5316-5326, 2004. (Pubitemid 39100466)
51. Gribben JG, Ryan DP, Boyajian R et al.: Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11(12): 4430-4436, 2005. (Pubitemid 40825633)
52. Arlen PM, Gulley JL, Parker C et al.: A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4): 1260-1269, 2006. (Pubitemid 43342517)
53. Lee AL WY, Pervaiz S, Fan W and Yang YY: Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci 11(2): 296-307, 2011.
54. Bräutigam K B-WJ, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N and Meinhold-Heerlein I: Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol pp. 1-12, 2010.
55. Lake RA and Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5(5): 397-405, 2005. (Pubitemid 40637831)
56. Gabrilovich DI: Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 8(1): 2-3, 2007.
57. Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC and Thor Straten P: Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57(11): 1735-1743, 2008.
58. Doyle A, Martin WJ, Funa K et al.: Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 161(5): 1135-1151, 1985. (Pubitemid 15011330)
59. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C and Brambilla E: Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201(2): 268-277, 2003. (Pubitemid 37258938)
60. Shivapurkar N, Reddy J, Matta H et al.: Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21(55): 8510-8514, 2002. (Pubitemid 36054892)
61. Pitti RM, Marsters SA, Lawrence DA et al.: Genomic amplification of a decoy receptor for FAS Ligand in lung and colon cancer. Nature 396(6712): 699-703, 1998. (Pubitemid 29003951)
62. Hopkins-Donaldson S, Ziegler A, Kurtz S et al.: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10(3): 356-364, 2003. (Pubitemid 36582373)
63. Sartorius UA and Krammer PH: Up-regulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97(5): 584-592,2002. (Pubitemid 34087795)
64. Sun S-Y, Yue P, Zhou J-Y et al.: Overexpression of Bcl2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer Cells. Biochemical and Biophysical Research Communications 280(3): 788, 2001.